Abstract
A Dose-Escalation Study of Venetoclax (ABT-199/GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have